Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, Daniel J George, Rahul Aggarwal, Elyn Riedel, Takayuki Sumiyoshi, Joseph D Schonhoft, Amanda Anderson, Ninghui Mao, Samuel Haywood, Brooke Decker, Tracy Curley, Wassim Abida, Felix Y Feng, Karen Knudsen, Brett Carver, Mario E Lacouture, Alexander W Wyatt, Dana Rathkopf
BACKGROUND: CC-115, a dual mTORC1/2 and DNA-PK inhibitor, has promising antitumour activity when combined with androgen receptor (AR) inhibition in pre-clinical models. METHODS: Phase 1b multicentre trial evaluating enzalutamide with escalating doses of CC-115 in AR inhibitor-naive mCRPC patients (n = 41). Primary endpoints were safety and RP2D. Secondary endpoints included PSA response, time-to-PSA progression, and radiographic progression. RESULTS: Common adverse effects included rash (31...
January 2024: British Journal of Cancer